1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Status:
Completed
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the
clinical and inflammatory findings of Behced Disease patients with neurologic and vascular
involvement.